UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
SEC FILE NUMBER
033-20897
--------------------
CUSIP NUMBER
423287 309
--------------------
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one) Form 10-K Form 10-KSB Form 20-F X Form 10-Q Form N-SAR
--- --- --- --- ---
For Period Ended: March 31, 2003
-----------------
Transition Report on Form 10-K
Transition Report on Form 20-F
Transition Report on Form 11-K
Transition Report on Form 10-Q
Transition Report on Form N-SAR
For the Transition Period Ended: ____________________________
Nothing in this form shall be construed to imply that the Commission has
verified any information herein.
If the notification related to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
- --------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
HELIX BIOMEDIX, INC.
- --------------------------------------------------------------------------------
Full Name of Registrant
- --------------------------------------------------------------------------------
Former Name if Applicable
22122 20TH Ave. SE
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Bothell, WA 98021
- --------------------------------------------------------------------------------
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12 b-25(b), the following
should be completed. (Check box if appropriate) [X]
(a) The reason described in reasonable detail in Part III of this form
could not be completed without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K or Form NSAR, or portion thereof, will
be filed on or before the fifteenth day following the prescribed due
date; or the subject quarterly report or transition report on Form
10-Q, or portion thereof will be filed on or before the fifth calendar
day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
PART III -- NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the
transition report or portion thereof, could not be filed within the prescribed
time period.
The registrant's Form 10-QSB cannot be filed without unreasonable effort and
expense to complete the document and obtain the appropriate approvals and
signatures.
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification:
Kerry D. Palmer 425 402-8400
--------------- ----------- -----------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s) [X] Yes [] No
- --------------------------------------------------------------------------------
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? [] Yes [X]No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
- --------------------------------------------------------------------------------
HELIX BIOMEDIX, INC.
-----------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date May 15, 2003 By /s/ Kerry D. Palmer
------------- --------------------------------
Kerry D. Palmer, Chief Financial
Officer